- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00635284
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
October 16, 2019 updated by: Celgene
A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.
Study Overview
Detailed Description
No extended description necessary
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas M.D. Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Each subject must meet the following criteria to be enrolled in this study.
- Male and female patients with histologically or cytologically confirmed diagnosis of cancer which is not amenable to curative therapy.
- Patients with advanced non-hematologic malignancies for whom no standard therapy exists.
- Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, pleural effusion, ascites, or lesions which do not fulfill RECIST criteria for metastatic disease)
- Off all therapy (inclusive of investigational therapies) for at least 4 weeks prior to study drug administration OR off all daily or weekly therapy (inclusive of investigational therapies) for at least 2 weeks prior to study drug administration and without any side effects associated with these therapies.
- Female patients of child-bearing potential must have a negative serum pregnancy test within 7 days prior to first study drug administration.
- Female patients who are postmenopausal must have 12 months of amenorrhea, surgically sterile, or must agree to the use of a physical method of non-hormonal contraception.
- Male patients must be surgically sterile or agree to the use of a barrier method of contraception.
- Life expectancy of > 3 months.
- ECOG Performance Status of 0-1.
- Patients must be able to provide informed consent indicating knowledge of his/her disease process, the investigational nature of the therapy, alternatives, benefits, and risks including potential side effects.
- Age ≥ 18 years of age.
- No major surgery within 4 weeks before treatment with ABI-009. (A biopsy is not considered major surgery).
- No chemotherapy, hormonal therapy, immunotherapy or radiotherapy within 4 weeks before treatment with ABI-009 (6 weeks for previous treatment with nitrosoureas, mitomycin, or extensive radiotherapy) and no immunosuppressive agents within 3 weeks before study entry (except corticosteroids used as antiemetics).
- No immunosuppressive agents within 3 weeks before study entry (except corticosteroids used as antiemetics).
Required Initial Laboratory Data:
- Hemoglobin > 9.0 g/dL
- WBC ≥ 3,000/µl
- ANC ≥ 1,500/µl
- Platelet count ≥ 100,000/µl
- Total Bilirubin ≤ ULN
- SGOT (AST) SGPT (ALT) ≤ 1.5 x ULN ≤ 1.5 x ULN
- Serum Cholesterol < 350 mg/dL
- Serum Triglyceride < 300 mg/dL
- Adequate renal function with serum creatinine < 1.5 mg/dL and/or creatinine clearance (cockroft formula) ≥ 60 mL/min.
- No active alcohol abuse, drug addiction, or psychotic disorders.
- No known concomitant genetic or acquired immunosuppressive diseases (such as AIDS).
- If obese, a patient must be treated with doses calculated using his/her actual BSA (The physician must be comfortable treating at the full BSA dose regardless of BSA).
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from the study.
- Pregnant or nursing women.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics.
- Patients have not recovered from adverse affects of radiation therapy or investigational agent within previous 28 days.
- Uncontrolled intercurrent illness that in the opinion of the investigator would limit compliance and tolerance to study requirements
- Patients with known brain metastases or leptomeningeal tumor involvement.
- Receiving any of the following: concomitant antitumor therapy or inhibitors of CYP3A4.
- Patients with history of interstitial lung disease and/or pneumonitis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABI-009
|
nab-rapamycin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009.
Time Frame: End of Study (EOS) and Follow Up
|
End of Study (EOS) and Follow Up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of ABI-009 in this patient population
Time Frame: End of Study (EOS) and Follow Up
|
End of Study (EOS) and Follow Up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ana M. Gonzalez, MD, M.D. Anderson Cancer Center
- Principal Investigator: Sant P. Chawla, MD, Sarcoma Oncology Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2007
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
March 7, 2008
First Submitted That Met QC Criteria
March 12, 2008
First Posted (Estimate)
March 13, 2008
Study Record Updates
Last Update Posted (Actual)
October 18, 2019
Last Update Submitted That Met QC Criteria
October 16, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
University of AlbertaWithdrawnLocally Advanced Solid Tumors | Metastatic Solid TumorsCanada
-
Genentech, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid TumorsAustralia, United States, Canada
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
Clinical Trials on ABI-009
-
Aadi Bioscience, Inc.Withdrawn
-
Seattle Children's HospitalAadi Bioscience, Inc.CompletedEpilepsy IntractableUnited States
-
Alexza Pharmaceuticals, Inc.Completed
-
Alexza Pharmaceuticals, Inc.CompletedParkinson's DiseaseNetherlands
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Not yet recruiting
-
Aadi Bioscience, Inc.RecruitingCancer | Endometrial Cancer | Tumor | Recurrent Endometrial Carcinoma | Endometrioid Endometrial Cancer | Endometrioid TumorUnited States
-
Compass TherapeuticsActive, not recruitingMetastatic Colorectal Cancer | Rectal Cancer | Colon CancerUnited States
-
Eisai Co., Ltd.Completed
-
Everfront Biotech Co., Ltd.Not yet recruitingPancreatic Cancer